Rational protein design has had a tremendous impact on pharmaceutical, agriculture, and chemical industries over the past 30 years, by focusing exclusively on individual proteins and their intrinsic activities. The next generation of protein design tasks will seek to modify function inside living cells, competing and interacting directly with pre-existing cellular machinery. Modifying systems in living cells will open a new wave of biotechnology applications, such as living drug implants and diagnostic tools.
There currently are no approved treatments for COVID-19, as global case counts increase daily. High infectivity and long time-to-recovery for COVID-19 cases is straining health-care systems globally. There is an urgent need to discover therapeutics that treat patients and improve clinical outcomes. Research and Development timelines associated with vaccines and new chemical entities will not reach clinics in time to mitigate the current patient surge, leaving drug repurposing as the most practical short-term solution.
In order to help deal with COVID-19 pandemic, there is an urgent need for development of fast, reliable, and sensitive tests that will be capable of detecting IgG and IgM proteins directly in people's blood.
Join a thriving innovation ecosystem. Subscribe now